Flot.bio x Philip Hemme

• Thomas Ybert, DNA Script 🇫🇷 | DNA Printing & Synthesis | E27

  We’re online 🇫🇷 with Thomas Ybert, the co-founder of DNA Script, the leading biotech for DNA printing of oligos. We talked about the commercialization of the first DNA printer. We also talked about company building at large and how to expand to the US successfully. ⭐️ ABOUT THE SPEAKER At just 30 years old, Thomas Ybert co-founded DNA Script in 2014 in Paris. Previously he worked in R&D at Sanofi before joining Total in the New Energies Division where he contributed to the bio jet-fuel project in collaboration with Amyris. It was here he developed his passion for manufacturing synthetic DNA which moved him from the world of academic research to a startup. 🔗 LINKS MENTIONED From 3 nucleotides to being a cornerstone technology for precision medicine, my journey creating an Enzymatic DNA Synthesis technology and company: https://www.linkedin.com/pulse/from-3-nucleotides-being-cornerstone-technology-precision-ybert-ykw3c?trackingId=HIpMVK4lTiOPcxcWeSsI4w%3D%3D&lipi=urn%3Ali%3Apage%3Ad_flagship3_search_srp_all%3BIW0XygKqT4Wbnq6s0mNP7Q%3D%3D DNA Script to Unveil Industry’s Most Versatile On-site, On-Demand DNA Printer at the World’s Largest Synthetic Biology Conference: https://www.biospace.com/dna-script-to-unveil-industry-s-most-versatile-on-site-on-demand-dna-printer-at-the-world-s-largest-synthetic-biology-conference DNA Script Appoints Marc Montserrat as CEO to Drive Long-Term Commercial Growth for Groundbreaking Enzymatic DNA Synthesis Platform: https://www.dnascript.com/press-releases/dna-script-appoints-marc-montserrat-as-ceo-to-drive-long-term-commercial-growth-for-groundbreaking-enzymatic-dna-synthesis-platform/ Towards Longer, Purer Oligonucleotides Thanks to Enzymatic DNA Synthesis: https://www.synbiobeta.com/read/towards-longer-purer-oligonucleotides-thanks-to-enzymatic-dna-synthesis 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/thomas-ybert-dna-script-dna-printing/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US Newsletter: http://eepurl.com/h_fnmH LinkedIn: https://www.linkedin.com/company/flot-bio/ X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro [00:02:06] One decade after the inception of DNA Printing [00:12:35] The problem DNA printing is solving [00:22:44] Reaching €20M sales [00:25:09] Productizing a science breakthrough [00:32:49] Thomas Ybert's transition from CEO to CSO [00:39:53] Early US expansion for DNA Script [00:49:22] Next steps for DNA Script [00:51:18] Quickfire [00:57:50] Thanks for listening

  --------  

  58:36
• Gunilla Osswald, BioArctic 🇸🇪 | Leqembi, Alzheimer’s disease | E26

  We’re at BIO-Europe in Stockholm 🇸🇪 with Gunilla Osswalld, the CEO of BioArctic, the inventor of one of the only drugs that have worked for Alzheimer's. We talked about the science and business behind Leqembi. We also talked about the Alzheimer’s field at large and transitioning from big pharma to biotech. — — — Thank you to today’s sponsor, Turbine, who is organizing a free Techbio event at JPM25 and is inviting you to join. Click the link to RSVP and secure one of the limited spots: https://www.turbine.ai/jpm25-event-registration — — — ⭐️ ABOUT THE SPEAKER Gunilla joined BioArctic in 2013 after many successful years in executive positions at Astra/AstraZeneca, including Vice President for the product portfolio of neurodegenerative diseases. Since joining BioArctic, the largest Swedish biotech, Leqembi, one of the only successful drugs for Alzheimer’s was approved. This was an invention of BioArctic that Eisai and Biogen have commercialized. This is a particularly impressive feat considering 98% of Alzheimer’s drugs fail. 🔗 LINKS MENTIONED- The CEO of BioArctic talks Leqembi and what's next in Alzheimer's, Parkinson's, ALS, and more: https://www.biotechtv.com/post/bioarctic-gunilla-osswald-september-21-2024 - Roche sees rapid amyloid clearing in Alzheimer's study, adjusts protocol after patient death: https://www.fiercebiotech.com/biotech/roche-sees-rapid-amyloid-clearing-early-alzheimers-study - Edwin Moses | How to build large biotech platforms | E13: https://flot.bio/episode/edwin-moses-biotech-platforms/ 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/gunilla-osswald-bioarctic-alzheimers/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro [00:02:24] Leqembi and BioArctic [00:10:40] Side effects of Leqembi for Alzheimer's treatment [00:17:03] Passing the blood-brain barrier for better Alzheimer's treatments [00:21:00] Market access for Leqembi in Europe [00:27:03] Gunilla Osswald's commitment to patients [00:31:55] Leaving AstraZeneca, transitioning to biotech [00:38:42] Unique culture at BioArctic [00:42:26] Alzheimer's field in Europe and at large [00:48:20] Quickfire [00:53:42] Thanks for listening

  --------  

  54:25
• Sean Marett 🇩🇪 | BioNTech, Art of Dealmaking | E25

  We’re in Hamburg with Sean Marett, who has been instrumental to the success of BioNTech for 12 years. We talked about the secrets behind BioNTech’s success. We also talked about the art of dealmaking and working with China. ⭐️ ABOUT THE SPEAKER Sean joined BioNTech in 2012 as part of the Management Board. He was instrumental in the growth of the company and global expansion through business development and product commercialization. Prior to BioNTech Sean worked in top companies such as GlaxoSmithKline, Pfizer, Evotec, and Lorantis. I first met Sean in 2015 in Berlin, when BioNTech had no website, but was already the largest private biotech in Europe. Now Sean has retired from BioNTech after 12 years but still aids the company as a specialist consultant. 🔗 LINKS MENTIONED - BioNTech Announces Planned Retirement of Sean Marett: https://investors.biontech.de/news-releases/news-release-details/biontech-announces-planned-retirement-sean-marett - BioNTech pays $800M to take control of potential Keytruda killer: https://www.fiercebiotech.com/biotech/biontech-pays-800m-take-control-potential-keytruda-killer - Sean Marett, COO at BioNTech, on the Future of mRNA Therapies - 2015: https://www.youtube.com/watch?v=6zrDKRvsAEU 📜 TRANSCRIPT Read the full transcript here: 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⏰ TIMESTAMPS - [00:00:00] Intro - [00:01:45] Sean Marett stepping down as CBO of BioNTech - [00:05:10] From Pfizer to BioNTech - [00:15:28] Building a biotech in Mainz - [00:29:02] The art of biotech dealmaking - [00:45:29] Mistakes in dealmaking - [00:57:45] Biotech dealmaking in China - [01:04:25] Managing energy - [01:08:17] Quickfire - [01:13:57] Thanks for listening

  --------  

  1:14:55
• Lovisa Afzelius, Flagship Pioneering 🇸🇪 | Company building, AI | E24

  In our first episode recorded live in front of an audience, we’re with Lovisa Afzelius, the General Partner of the European branch of Flagship Pioneering 🇸🇪 We talk about Flagship, including its EU activities. We also talk about company-building and Lovisa’s personal journey to be one of the leading Swedish leaders in biotech. ⭐️ ABOUT THE SPEAKER Lovisa is an icon in the EU biotech and pharma world, having been a CEO, co-founder, president, board chairman, and executive director in many emerging companies. Joining Flagship in 2020, she became the founding CEO of Alltrna, and co-founded/CEO of Apriori Bio, Metaphore Biotechnologies, and Prologue Medicines. Lovisa has received many accolades. A few include being listed on Inc. Magazine’s Female Founders 250 List in 2024, 2023 she featured in the PharmaVoice 100 list of life science industry leaders. 🔗 LINKS MENTIONED - tRNA therapies, Lovisa Afzelius, Founding CEO, Theonie Anastassiadis, Co-founder & CIO, Alltrna: https://open.spotify.com/episode/3JaGad1YednEhExnK4Xl2L?si=7G65_6u_TyeB3Rmn5hzZYw&nd=1&dlsi=4f17dae5cf3f4306 - Agnete Fredriksen, Nykode | Being one of the top 50 women in 🇪🇺 Bio | E07: https://flot.bio/episode/agnete-fredriksen-top-women-bio/ - Flagship Pioneering website: https://www.flagshippioneering.com/ - Otello Stampacchia, Omega Funds 🇮🇹 | Competition, Boston & Pasta | E18: https://flot.bio/episode/otello-stampacchia-omega-funds/ 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/lovisa-afzelius-flagship-pioneering/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro [00:02:08] Flagship Pioneering and their EU biotech initiatives [00:06:18] Being creative in many biotech spheres [00:08:37] Why invest 50m in first seed Series A every time? [00:11:42] The Flagship Pioneering business model: invest early [00:15:57] VC-created vs founder-led biotechs [00:17:46] Raising one of the largest biotech funds [00:19:19] Flagship Pioneering’s biggest returns [00:22:36] AI & biotech [00:26:31] What does success mean to Flagship Pioneering [00:29:20] How to help biotech spinoffs grow and advice for women to be biotech leaders [00:34:03] How to move from computational to translation sciences & bring drugs to market faster [00:37:14] What can the EU learn from the US to create biotechs [00:40:36] How do you bridge the gap between biotech company creation in the US vs EU [00:43:07] Lessons for an early-stage biotech career [00:47:18] How to attract the best biotech talent [00:48:38] Moving to Boston [00:52:13] Quickfire [00:55:41] Thanks for listening

  --------  

  59:16
• Szabolcs Nagy, Turbine 🇭🇺 | AI in Biotech, Simulation | E23 [Sponsored]

  We’re in Budapest with Szabolcs Nagy, the founder of Turbine, one of the leading companies for AI in biotech in the world. We talked about AI in biotech at large. We also cover the differences between opening a platform versus doing proprietary drug development and building the company from central Europe. __ This episode is sponsored by Turbine, which can improve your drug development. Learn more at https://shorturl.at/w3Im6 __ ⭐️ ABOUT THE SPEAKER I’ve known Szabolcs since 2017 when he joined Bayer’s accelerator in Berlin. I found him incredibly inspiring back then and still to this day. Szabi began his serial entrepreneurship with the creation of a cybersecurity startup. Once that was acquired, he launched himself into the biotech scene with the founding of Turbine in 2015. 🔗 LINKS MENTIONED - Accenture's Investment in Turbine Enhances AI-Powered Cell Simulations for Biopharma R&D: https://www.biopharmatrend.com/post/806-accentures-investment-in-turbine-enhances-ai-powered-cell-simulations-for-biopharma-rd/ - After a tough year, Exscientia folds into Recursion to create an AI superpower: https://www.fiercebiotech.com/biotech/after-tough-year-exscientia-folds-recursion-create-ai-super-power 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/szabolcs-nagy-ai/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. [🎙️](https://x.com/FlotBio) ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro [00:01:47] AI in Biotech [00:09:03] Open platform vs proprietary drug development [00:29:09] Pricing and value of AI technology in biotech [00:38:19] Working with the average biotech [00:42:42] History of Turbine and Szabolcs Nagy [00:53:36] Data-driven drug development [00:58:04] Quickfire

  --------  

  1:04:44

Fler podcasts i Vetenskap

Trendiga poddar i Vetenskap

Om Flot.bio x Philip Hemme